Innate Immunity: Complement and Beyond
Innate Immunity: Complement and Beyond
批准号:
10464340
负责人:
Thale Cross Jarvis
金额:
$1.1万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
2022
资助国家:
美国
项目状态:
已结题
起止时间:
2022-03-21 至 2023-02-28
关键词:
AcademiaAddressAreaAutoimmunityAwarenessBehaviorBiologyBiotechnologyBody partCOVID-19Cell DeathCell physiologyChromatin StructureClinicalCognitionCollaborationsComplementDisciplineDiseaseEducational workshopEyeFertilizationFosteringFutureGenesHealthHost DefenseHumanImmunityIndustryInfectionInflammasomeInnate Immune ResponseIntuitionKnowledgeLearningLyticMaintenanceMentorsMetabolismMethodologyNatural ImmunityNormal CellOutcomePathogen detectionRegulationResearchResearch PersonnelRoleSentinelSerumSystemSystems BiologyTherapeuticTimeToll-like receptorsTretinoinUpdateUtahWorkbehavior changecareerclinical practicecombatcomplement systememerging pathogenholistic approachhuman diseaseimprovedinterestnovelpathogenpostersprogramsreceptorsymposiumtherapeutic target
中文摘要
摘要
请求为题为“先天免疫:补充和超越”的Keystone专题讨论会会议提供支助
由Claudia Kemper,Christoph Binder和Feng Shao博士组织。会议将于
2022年4月3日至6日,犹他州雪鸟。
先天免疫是宿主防御感染和有害自我的支柱。病原体或危险
识别系统(PRRs),包括Toll样受体(TLR)、炎性小体和视黄酸诱导的
基因I(RIG-I)样受体被广泛认为是先天免疫应答的中心节点,
成为免疫研究的斯台普斯。然而,补体系统通常引起的反应要少得多。
尽管从进化的角度来看,它是最古老的PRR,但它对研究充满热情。然而,这种观点是
虽然补体系统曾经被认为是一个纯粹的溶解性病原体杀手,但现在已经认识到,
作为正常细胞生理的活跃细胞内协调者。这一点,加上认识到,
越来越多的人类疾病,甚至是COVID-19,涉及补体干扰,已经刺激了一个
重振了对补体生物学及其治疗靶向的兴趣。然而,我们对
补体发挥非典型的活动,它如何与其他PRR相交是稀疏的。这个Keystone
专题讨论会将提供一个及时的帐户,最近的范式转变,我们的理解,
补体/PRR指导的免疫,特别关注基本细胞过程中的新兴作用
包括调节染色质结构、代谢、细胞死亡、清除细胞碎片/尸体,以及
维持正常的CNS功能。第二个重点是探索这些新的PRR的异常功能是如何发生的。
活动导致感染和自身免疫,但也导致不太直观的临床状况,如
认知和行为。PRR生物学的这种整体性和“互补性”优势点汇集了
来自学术界和工业界的跨学科研究人员,
在利用补体对抗人类疾病方面,为生物医学进步开展合作。
英文摘要
ABSTRACT
Support is requested for a Keystone Symposia conference entitled Innate Immunity: Complement and Beyond
organized by Drs. Claudia Kemper, Christoph Binder and Feng Shao. The conference will be held in
Snowbird, Utah from April 3-6, 2022.
Innate immunity is a pillar of the host’s defense against infection and noxious self. Pathogen or danger
recognition systems (PRRs) including toll-like receptors (TLRs), inflammasomes, and retinoic acid-inducible
gene I (RIG-I) like receptors are broadly recognized as central nodes of innate immune responses and have
been staples of immunity research. The complement system, however, generally evokes much less
enthusiasm in research, despite being the oldest PRR from an evolutionary perspective. Yet, this view is
changing; while the complement system was once viewed as a mere lytic pathogen-killer, it is now recognized
as an active intracellular orchestrator of normal cell physiology. This, together with the realization that an
increasing number of human diseases, even COVID-19, involve complement perturbations, has spurred a
reinvigorated interest in complement biology and its therapeutic targeting. However, our knowledge of how
complement exerts non-canonical activities and how it intersects with other PRRs is sparse. This Keystone
Symposia conference will provide a timely account of recent paradigm shifts in our understanding of
complement/PRR-instructed immunity with a specific eye on emerging roles in basic cellular processes
including regulation of chromatin structure, metabolism, cell death, clearance of cellular debris/corpses, and
maintenance of normal CNS function. A second focus is on exploring how aberrant function of these new PRR
activities contribute to infection and autoimmunity but also to less intuitive clinical conditions like changes in
cognition and behavior. This holistic and ‘complement-inclusive’ vantage-point on PRR biology brings together
interdisciplinary investigators from academia and industry for cross-fertilization of novel ideas and
collaborations towards biomedical progress in harnessing complement to combat human disease.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Bioenergetics in Health and Diseases
-
批准号:10609120
-
项目类别:
-
资助金额:$1.74万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Autophagy and Neurodegeneration: Mechanisms to Therapies
-
批准号:10608666
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Adipose Tissue: Energizing Good Fat
-
批准号:10609127
-
项目类别:
-
资助金额:$2.02万
-
财政年份:2023
-
负责人:Thale Cross Jarvis
-
依托单位:
Cancer Neoantigens, Vaccines and Viruses
-
批准号:10233861
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Small Regulatory RNAs: From Bench to Bedside
-
批准号:10462420
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Engineering Multi-Cellular Living Systems
-
批准号:10462913
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Malaria: Confronting Challenges From Drug Discovery to Treatment
-
批准号:10468493
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Gut-Brain Axis
-
批准号:10467819
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
The Human Microbiome: Ecology and Evolution
-
批准号:10391370
-
项目类别:
-
资助金额:$0.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Modern Phenotypic Drug Discovery: From Chemical Biology to Therapeutics
-
批准号:10468419
-
项目类别:
-
资助金额:$1.72万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Progress in Vaccine Development for Infectious Diseases
-
批准号:10467880
-
项目类别:
-
资助金额:$0.55万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Tissue Fibrosis and Repair: Mechanisms, Human Disease and Therapies
-
批准号:10462412
-
项目类别:
-
资助金额:$1.8万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Drug Delivery to the Brain: Challenges and Progress
-
批准号:10540503
-
项目类别:
-
资助金额:$1.77万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neurocircuitry of Social Behavior
-
批准号:10540465
-
项目类别:
-
资助金额:$1.2万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Resolution of Inflammation
-
批准号:10469175
-
项目类别:
-
资助金额:$0.9万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Organoids as Tools for Fundamental Discovery and Translation
-
批准号:10469084
-
项目类别:
-
资助金额:$1.5万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Novel Approaches Against Emerging Antimicrobial Resistance
-
批准号:10391767
-
项目类别:
-
资助金额:$1.1万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Precision Genome Engineering
-
批准号:10391367
-
项目类别:
-
资助金额:$2.22万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Neuronal Control of Appetite
-
批准号:10468571
-
项目类别:
-
资助金额:$2.0万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
Inborn Errors In Immunity
-
批准号:10540279
-
项目类别:
-
资助金额:$1.6万
-
财政年份:2022
-
负责人:Thale Cross Jarvis
-
依托单位:
海外基金